Gene Therapy Research Institution Overview
- Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
2
Gene Therapy Research Institution General Information
Description
Operator of a drug development company intended to carry out R&D on gene therapy technology targeting mainly neurodegenerative diseases. The company specializes in developing gene therapies for refractory diseases primarily focusing on Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease, enabling patients to get therapies while suffering from refractory diseases.
Contact Information
Website
www.genetherapy-ri.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Life Innovation Center 414
- 25-22, Tonomachi 3-chome Kawasaki-ku, Kawasaki-shi
- Kanagawa, 210-0821
- Japan
+81 000-000-0000
Gene Therapy Research Institution Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 24-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 24-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 1. Secondary Transaction - Private | 19-Feb-2016 | $163K | 00000 | Completed | Pre-Clinical Trials |
Gene Therapy Research Institution Patents
Gene Therapy Research Institution Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210292790-A1 | Method for enhancing gene expression using aav vector | Pending | 30-Jul-2018 | 0000000000 | |
| JP-WO2020026968-A1 | Method of enhancing gene expression by aav vector | Pending | 30-Jul-2018 | 000000000 | |
| EP-3831949-A1 | Method for enhancing gene expression by aav vector | Pending | 30-Jul-2018 | C12N15/86 |
Gene Therapy Research Institution Executive Team (3)
Gene Therapy Research Institution Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Masako Kawase Ph.D | Gene Therapy Research Institution | Board Member | 000 0000 |
| Shin-ichi Muramatsu Ph.D | Gene Therapy Research Institution | Chief Revenue Officer & Board Member | 000 0000 |
| Shunta Nojiri | Gene Therapy Research Institution | Chief Financial Officer & Board Member | 000 0000 |
| Takashi Nishibori | Gene Therapy Research Institution | Board Member | 000 0000 |
| Toshihiko Sato MD | Gene Therapy Research Institution | Board Member | 000 0000 |
Gene Therapy Research Institution Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alfresa | Corporation | Minority | 000 0000 | 000000 0 | |
| Medical Incubator Japan | Venture Capital | Minority | 000 0000 | 000000 0 |
Gene Therapy Research Institution Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000-0000000 | 02-Aug-2017 | 00000 0000 | Biotechnology | 000000000 |